RE: Mighty Vlad2 Mar 2022 22:02
He made a bad decision that has cost us plenty in the SP. But it's done. I'd suggest market conditions and liquidity have contributed heavily since in stunting any sort of recovery whilst pre clinical. Seasoned pharma investors will tell pre clinical drugs are a pipe dream. Clinical is when things become to close in on a the reality of success.
However, the mess up has happened. You want an apology? haha ok. I am sure he had reasons but it seems to have contributed heavily to the shoddy SP.
You do know why people invest in pharma though dont you? For the astronomical gains potential that lands when a drug is proven to be safe and effective. Which can come as early as phase 1/2a conclusion for oncology trial studies.
The most recent RNS confirms CAR T is moving forward via remote dialogue with FDA towards the IND app reaching approval. Once they're happy then this confirms the drug safety profile, efficacy, manufacturing and trial plan looks plausibly safe to deliver and prove up.
Then the trial plans submitted to FDA can be implemented.
Now imagine... just imagine.... if the drug is proven to be safe and work effectively on humans and save lives?
Imagine HEMO have millions in the bank and have recruited specifically an experienced negotiator of non-dilutive finance with sponsorship and grant provers to top up these millions to ensure trials are concluded on time.
There is a lot of talk that HEMO has failed. Hell, the SP suggests its failed. Well I'd suggest there is plenty of legs little old HEMO and the scientific nouse they have working on the products is second to none. You do your research and you make a decision. You buys your ticket and you takes your chance...
Good luck long term holders. I keep the faith.